Ivabradine Zydus (Ivabradine Hydrochloride)

Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions.

• Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate without affecting contractility.
• Heart failure with reduced ejection fraction (HFrEF): decreases heart rate to improve ventricular filling and functional capacity.
• Symptomatic sinus tachycardia (off‑label in some regions): may be used to control elevated resting heart rate when other agents are unsuitable.

• Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which is responsible for spontaneous depolarization during diastole. By blocking this inward sodium‑potassium mixed current, the drug slows the pacemaker activity, leading to a reduction in heart rate while preserving myocardial contractility and intracardiac conduction.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena.
• Bradycardia: heart rate slower than intended.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Fatigue or general weakness.
• Nausea or gastrointestinal discomfort.

Serious or Rare Side Effects

• Symptomatic severe bradycardia requiring medical attention.
• Atrial fibrillation or other arrhythmias.
• Persistent visual impairment.
• Severe hypotension.
• Allergic reactions such as rash or angioedema.
• Myocardial ischemia exacerbation.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Cardiac monitoring: assess resting heart rate and ECG prior to starting treatment.
• Concomitant beta‑blockers: avoid excessive bradycardia by adjusting doses.
• CYP3A4 inhibitors: consider dose reduction or increased monitoring.
• Renal impairment: use with caution and monitor renal function.
• Pregnancy: safety not established; avoid unless benefit outweighs risk.
• Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine can interact with several medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma concentrations.
• Verapamil or diltiazem: combined use can cause excessive bradycardia.
• Other potent heart‑rate lowering agents (high‑dose beta‑blockers): risk of severe bradycardia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Drugs that prolong QT interval (certain antidepressants, antipsychotics): monitor ECG for arrhythmia risk.
• Diuretics causing electrolyte shifts: watch for hypotension and electrolyte abnormalities.